Understanding the Diagnostic Challenge of Sellar Lesions

Sellar region lesions often present significant diagnostic challenges for neurosurgeons and endocrinologists due to overlapping clinical and radiological features. Specifically, Rathke’s cleft cysts (RCCs) and papillary craniopharyngiomas (PCPs) share a common embryological origin from Rathke’s diverticulum. A recent study highlights the critical importance of evaluating the BRAF V600E Rathke's cyst status to refine these diagnoses. Precise identification is essential because these lesions involve distinct treatment pathways and vastly different clinical outcomes.

Researchers retrospectively reviewed 383 cases at Beijing Tiantan Hospital to evaluate differentiating markers. They utilized BRAF V600E and CTNNB1 immunohistochemistry (IHC) to analyze histological overlaps. Furthermore, the team confirmed BRAF results through Sanger sequencing. Notably, histological findings showed that 56.5% of cases exhibited epithelial squamous metaplasia (SM). Within these areas of SM, 10.1% of the total cases tested positive for the BRAF V600E mutation. Consequently, these specific cases underwent reclassification as PCPs.

Clinical Utility of BRAF V600E Rathke's cyst Testing

The presence of the BRAF V600E Rathke's cyst mutation correlates strongly with increased proliferative activity. For instance, the study observed elevated Ki-67 indices concentrated in the basal layer of the epithelium. Therefore, the molecular profile provides a much more reliable indicator of tumor behavior than morphology alone. Most importantly, Kaplan-Meier analysis demonstrated that mutation-positive cases had significantly worse progression-free survival. This finding suggests that what clinicians initially diagnose as a benign cyst may actually behave like an aggressive tumor.

In addition to surgical implications, these molecular markers offer a roadmap for postoperative management. Since BRAF-positive lesions are prone to early recurrence, clinicians should recommend close radiological monitoring. Additionally, the identification of this mutation opens the door for targeted adjuvant therapies in recurrent cases. Consequently, the authors suggest that BRAF V600E testing should become standard for all RCC cases, particularly those showing squamous metaplasia.

Frequently Asked Questions

Why is BRAF V600E testing necessary for Rathke's cleft cysts?

Testing identifies cysts that are actually papillary craniopharyngiomas. These lesions require closer monitoring and potentially more aggressive management due to higher recurrence risks.

What role does squamous metaplasia play in diagnosis?

Squamous metaplasia in Rathke's cleft cysts often mimics the histological features of papillary craniopharyngiomas. This overlap makes molecular markers like BRAF V600E essential for an accurate diagnosis.

How does the BRAF V600E mutation affect patient follow-up?

Patients with BRAF-positive lesions have a higher risk of early recurrence. As a result, doctors often advise more frequent imaging and consider adjuvant therapies to manage tumor progression effectively.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

Shee LY et al. Surgical implications of BRAF V600E-positive Rathke's cleft cysts: prediction of early recurrence based on reclassification to papillary craniopharyngioma. J Neurosurg. 2026 May 08. doi: 10.3171/2025.12.JNS251886. PMID: 42102398.

Schweizer L et al. BRAF V600E analysis for the differentiation of papillary craniopharyngiomas and Rathke's cleft cysts. Neuropathol Appl Neurobiol. 2015;41(6):733-42. doi: 10.1111/nan.12201.

Candy N et al. The role of BRAF testing of Rathke's cleft cysts to identify missed papillary craniopharyngioma. Pituitary. 2025 Feb 03. doi: 10.1007/s11102-025-01501-8.